NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) has announced the appointment of David Choi as its new Chief Accounting Officer, effective March 12, 2026. This strategic move comes as the company advances its clinical-stage biotechnology platform focused on developing novel therapies for central nervous system cancers. Choi, who has over a decade of experience in accounting and financial reporting, will oversee the company's accounting, financial reporting, internal controls, and corporate governance functions. His employment agreement includes a base salary of $162,500 per year and participation in the company's 2023 Equity Incentive Plan, which grants him 170,000 restricted shares. The vesting schedule for these shares includes immediate vesting of 53,333 shares, with additional shares vesting over the next year based on performance metrics. This appointment is seen as a pivotal step for NeOnc as it prepares for accelerated clinical trials and corporate growth, emphasizing the importance of maintaining rigorous financial controls and governance during this critical phase.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.